360 Financial’s Pfizer PFE Stock Holding History

360 Financial’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,760	Closed	-$208K	–	91
2022 Q4	$208K	Hold	4,760	–	–	0.14%	77
2022 Q3	$208K	Buy	4,760 +470	+11%	+$22.8K	0.14%	74
2022 Q2	$220K	Sell	4,290 -470	-10%	-$24K	0.13%	69
2022 Q1	$242K	Sell	4,760 -100	-2%	-$5.19K	0.12%	79
2021 Q4	$287K	Sell	4,860 -100	-2%	-$4.96K	0.13%	72
2021 Q3	$213K	Buy	+4,960	New	+$220K	0.11%	80

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

360 Financial's PFE Position: Q1 2023 in Review

360 Financial sold out of Pfizer (PFE) in Q1 2023, closing a stake of 4,760 shares — an estimated $208K sold.

360 Financial first reported a position in PFE in Q3 2021 and held it in 6 quarters. The position peaked at $287K in Q4 2021. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

360 Financial reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
360 Financial sold 4,760 Pfizer shares in Q1 2023, an estimated $208K.
360 Financial first reported a position in Pfizer in Q3 2021 and held it in 6 quarters.
360 Financial's Pfizer position peaked at $287K in Q4 2021.
3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on 360 Financial's 13F filing for Q1 2023, filed 11 Apr 2023.